High M2 ratio (CD163+/CD68+) in the tumor stroma is a potential marker for predicting malignant clinical outcomes in NSCLC patients, and consideration of M2 ratio and VEGF-C expression in combination may enhance the accuracy of prognostic prediction. Here, CD163 is linked to non-small cell lung carcinoma.